Study ID: ACCRU RC1126
Description:

A Randomized Phase II Trial of Erlotinib alone or in combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Location:
Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD
Disease:
Non-Small Cell Lung Cancer
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list